SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging as investors react to strong earnings results that highlighted significant revenue growth and a positive shift to profitability, effectively countering bearish short-selling narratives. Community sentiment is overwhelmingly bullish, with active discussions focusing on the potential for a major short squeeze and the company's aggressive expansion plans in the AI cloud infrastructure sector.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a strong quarterly report that exceeded revenue expectations and highlighted an accelerating demand for AI infrastructure, fueled by a massive and growing backlog. While the company's robust forward guidance and expanded customer commitments have ignited bullish momentum, investors remain deeply divided, with many debating the sustainability of the company's heavy debt load and high capital expenditure relative to its current profitability.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a massive earnings report featuring an earnings beat, record backlog, and significantly raised revenue guidance that topped analyst expectations. The community is actively debating the potential for a major short squeeze given the stock's high short interest and company confirmation that it currently has no plans to utilize its previously announced ATM program.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is currently trading in a tight, range-bound pattern as investors brace for the latest inflation data release, which many in the community anticipate will be heavily managed or "cooked" by government officials to appear in line with expectations. Despite ongoing geopolitical tensions and skepticism regarding economic health, traders are intensely focused on how this key data point will dictate the next move for interest rates and the broader market's ability to maintain its current levels.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing increased trader interest ahead of its upcoming earnings report, with the community actively debating whether the company's strong revenue growth and significant contract backlog will lead to a breakout. While investors remain cautious regarding sector-wide volatility and broader market headwinds, many are closely monitoring the stock's ability to maintain upward momentum as it builds out its launch and defense capabilities.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp is facing heightened volatility following a significant downward revision to its 2026 revenue guidance, attributed to lower market prices for antimony and delivery shifts. Despite the financial miss and resulting share price pressure, the community remains actively divided between investors frustrated by management's execution and those maintaining a bullish long-term thesis centered on the company's status as the only fully integrated domestic antimony producer.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing intense momentum as the community reacts to positive Phase 3 Voyage study results for its lead anxiety drug, with traders actively debating the stock's valuation, dilution impacts, and potential for further clinical breakthroughs. Investors are closely monitoring price action as the company shifts from a developmental asset toward potential commercial readiness, keeping the symbol trending due to its volatile mix of breakthrough clinical milestones and institutional-led equity offerings.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is surging following an earnings report that highlighted a significant revenue jump and an increased revenue outlook, fueling intense community excitement around a potential short squeeze. Investors are actively discussing the company's critical role as a high-precision manufacturing supplier for the aerospace and defense sectors, with many speculating that strong industrial demand will drive further gains.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber, Inc. is gaining significant attention from investors as it navigates a volatile period, with recent community discussions focused on its unique retrofit strategy for AI infrastructure and its strategic equity stake held by Bit Digital. The community is closely monitoring the stock's support levels and potential for a breakout, driven by strong AI demand and institutional interest, despite some concerns regarding valuation, short interest, and sector-wide regulatory headwinds.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investor sentiment remains bullish following impressive Q2 earnings that showed strong same-store sales and robust traffic growth, effectively silencing Cyclospora-related concerns. While the stock has faced some valuation-based volatility and short-term profit-taking, the community remains divided between those who view it as a high-growth 'best of breed' long-term compounder and skeptics wary of its premium P/E multiple.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Appoints James Levine as Chief Financial Officer Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire SYDNEY, June 2, 2026 SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a...

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire SYDNEY, May 26, 2026 Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging...

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Kazia Therapeutics Strengthens Scientific...

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug...

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Equity

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.88
Prev Close	$13.95
Open	$13.99
Dividend Yield	0.00%
50-Day Moving Average	$13.09
Beta	1.44
Avg. Volume	196,263.56
PE Ratio	-2.03

52-Week High	$17.40
52-Week Low	$4.86
Market Capitalization	$158.61M
EPS (Annual)	-$12.23
Price to Book	5.08
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info